Skip to main content
Fig. 3 | BMC Geriatrics

Fig. 3

From: Assessing the effectiveness of statin therapy for alleviating cerebral small vessel disease progression in people ≥75 years of age

Fig. 3

Effect of rosuvastatin on the progression of cerebral small vessel disease in the clinical trial. a The trends of changes in WMH volume; b the trends of changes in WMH-to-ICV ratio; c the cumulative hazard of the risk of WMH progression identified by the Fazekas scale; d the cumulative hazard of the risk of lacune progression; e the cumulative hazard of the risk of EPVS progression; f the cumulative hazard of the risk of microbleed progression. Abbreviations list: WMH, white matter hyperintensities; ICV, intracranial volume; EPVS, enlarged perivascular space

Back to article page

BMC Geriatrics

ISSN: 1471-2318

Contact us